Table 3.
Theranostic nanoparticles for myocardial infarction, ischemic heart and ischemic injury
| Carrier nanoparticles material | Imaging agent and Imaging modality | Therapeutics/ drugs |
Target | Binding ligand | Disease | Ref. |
|---|---|---|---|---|---|---|
| Gold nanoparticles (AuNPs) | Cy 5 -Fluorescence | DNAzyme | Pro-inflammatory cytokine tumor necrosis factor-a gene (TNF-a gene) | TNF-a mRNA: GGACACCAUGAGCAC | Myocardial infarction | 101 |
| Iron oxide nanoparticles | Iron oxide - PET, CT & MRI | Mitochondrial transplantation | N/A | N/A | Ischemic Heart | 107 |
| Copolyoxalate polymer nanoparticles | Rubrene - Fluorescence | 4-AN, HPOX | H2O2 | HPOX | Ischemia- reperfusion injury |
110 |
| Iron oxide nanoparticles | Iron oxide - MRI | Stem cell | CD45-exogenous bonemarrow-derived stem cells; endogenous CD34-positive cells to injuredcardiomyocytes | Anti-CD45 and anti- myosin light chain (MLC) antibodies; magnetic attraction | Injured cardiomyocytes | 106 |